Peringatan Keamanan

The expected signs and symptoms with overdosage of albuterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis).Label In particular, the signs of salbutamol overdosage are significant tachycardia and/or significant muscle tremor.F3265,F3268

Hypokalaemia may occur following overdosage with salbutamol.F3265 Serum potassium levels should be monitored.F3265

Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.F3265,F3268

Salbutamol is categorized as Pregnancy Category C.Label There are no adequate and well-controlled trials with salbutamolc or albuterol sulfate in pregnant women.Label During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with salbutamol.Label Some of the mothers were taking multiple medications during their pregnancies.Label No consistent pattern of defects can be discerned, and a relationship between salbutamol use and congenital anomalies has not been established.Label Animal reproduction studies in mice and rabbits revealed evidence of teratogenicity.Label Salbutamol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetusLabel]. Women should be advised to contact their physicians if they become pregnant while taking salbutamol.Label

Since there exists a potential for beta-agonist interference with uterine contractility, the use of salbutamol during labour should be restricted to those patients in whom the benefits clearly outweigh the risk.Label

Plasma levels of albuterol sulfate and HFA-134a after inhaled therapeutic doses are very low in humans, but it is not known whether the components of salbutamol are excreted in human milk.Label Because of the potential for tumorigenicity shown for albuterol in animal studies and lack of experience with the use of salbutamol by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.Label Caution should be exercised when salbutamol is administered to a nursing woman.Label

The safety and effectiveness of salbutamol in children younger than 4 years of age has not yet been established.Label

Clinical trials of VENTOLIN HFA did not include sufficient numbers of subjects aged 65 years and older to determine whether older subjects respond differently than younger subjects.Label Other reported clinical experience has not identified differences in responses between the elderly and younger patients.Label In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.Label

The LD50 value was determined to be 1100 mg/kg (orally in mice).

Albuterol

DB01001

small molecule approved vet_approved

Deskripsi

Salbutamol (Albuterol USAN) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.Label,A174379,A174400

Struktur Molekul 2D

Berat 239.3107
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life of inhaled or oral salbutamol has been recorded as being between 2.7 and 5 hours while the apparent terminal plasma half-life of albuterol has been documented as being approximately 4.6 hours.[F3265,Label]
Volume Distribusi The volume of distribution recorded for intravenously administered salbutamol has been recorded as 156 +/- 38 L.[A174379]
Klirens (Clearance) The renal clearance of salbutamol has been documented as 272 +/- 38 ml/min after oral administration and 291 +/- 70 ml/min after intravenous administration.[A174379] Furthermore, the renal clearance of the predominant sulfate conjugate metabolite was recorded as 98.5 +/- 23.5 ml/min following oral administration.[A174379]

Absorpsi

Following inhalation, salbutamol acts topically on bronchial smooth muscle and the drug is initially undetectable in the blood.F3265 After 2 to 3 hours low concentrations are seen, due presumably to the portion of the dose which is swallowed and absorbed in the gut.F3265 In particular, the systemic levels of salbutamol are low after inhalation of recommended doses.Label A trial conducted in 12 healthy male and female subjects using a higher dose (1,080 mcg of albuterol base) showed that mean peak plasma concentrations of approximately 3 ng/mL occurred after dosing when salbutamol was delivered using propellant HFA-134a.Label The mean time to peak concentrations (Tmax) was delayed after administration of VENTOLIN (salbutamol) HFA (Tmax = 0.42 hours) as compared with CFC-propelled salbutamol inhaler (Tmax = 0.17 hours).Label

Metabolisme

Salbutamol is not metabolized in the lung but is converted in the liver to the 4'-o-sulphate (salbutamol 4'-O-sulfate) ester, which has negligible pharmacologic activity.F3265,F3268 It may also be metabolized by oxidative deamination and/or conjugation with glucuronide.F3265,F3268 Salbutamol is ultimately excreted in the urine as free drug and as the metabolite.F3265,F3268

Rute Eliminasi

After oral administration, 58-78% of the dose is excreted in the urine in 24 hours, approximately 60% as metabolites.F3265,F3268 A small fraction is excreted in the feces.F3265,F3268

Interaksi Obat

1580 Data
Loxapine The therapeutic efficacy of Salbutamol can be decreased when used in combination with Loxapine.
Valsartan Salbutamol may decrease the antihypertensive activities of Valsartan.
Ramipril Salbutamol may decrease the antihypertensive activities of Ramipril.
Remikiren Salbutamol may decrease the antihypertensive activities of Remikiren.
Olmesartan Salbutamol may decrease the antihypertensive activities of Olmesartan.
Minoxidil Salbutamol may decrease the antihypertensive activities of Minoxidil.
Trandolapril Salbutamol may decrease the antihypertensive activities of Trandolapril.
Benazepril Salbutamol may decrease the antihypertensive activities of Benazepril.
Candoxatril Salbutamol may decrease the antihypertensive activities of Candoxatril.
Nitroglycerin Salbutamol may decrease the antihypertensive activities of Nitroglycerin.
Metyrosine Salbutamol may decrease the antihypertensive activities of Metyrosine.
Cryptenamine Salbutamol may decrease the antihypertensive activities of Cryptenamine.
Candesartan cilexetil Salbutamol may decrease the antihypertensive activities of Candesartan cilexetil.
Eprosartan Salbutamol may decrease the antihypertensive activities of Eprosartan.
Quinapril Salbutamol may decrease the antihypertensive activities of Quinapril.
Telmisartan Salbutamol may decrease the antihypertensive activities of Telmisartan.
Irbesartan Salbutamol may decrease the antihypertensive activities of Irbesartan.
Deserpidine Salbutamol may decrease the antihypertensive activities of Deserpidine.
Pentolinium Salbutamol may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Salbutamol may decrease the antihypertensive activities of Trimethaphan.
Captopril Salbutamol may decrease the antihypertensive activities of Captopril.
Cilazapril Salbutamol may decrease the antihypertensive activities of Cilazapril.
Saprisartan Salbutamol may decrease the antihypertensive activities of Saprisartan.
Spirapril Salbutamol may decrease the antihypertensive activities of Spirapril.
Debrisoquine Salbutamol may decrease the antihypertensive activities of Debrisoquine.
Sitaxentan Salbutamol may decrease the antihypertensive activities of Sitaxentan.
Diethylnorspermine Salbutamol may decrease the antihypertensive activities of Diethylnorspermine.
Temocapril Salbutamol may decrease the antihypertensive activities of Temocapril.
Hexamethonium Salbutamol may decrease the antihypertensive activities of Hexamethonium.
Rauwolfia serpentina root Salbutamol may decrease the antihypertensive activities of Rauwolfia serpentina root.
Angiotensin 1-7 Salbutamol may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Salbutamol may decrease the antihypertensive activities of Imidapril.
BQ-123 Salbutamol may decrease the antihypertensive activities of BQ-123.
Dihydralazine Salbutamol may decrease the antihypertensive activities of Dihydralazine.
Zofenopril Salbutamol may decrease the antihypertensive activities of Zofenopril.
Guanoxan Salbutamol may decrease the antihypertensive activities of Guanoxan.
Delapril Salbutamol may decrease the antihypertensive activities of Delapril.
Vincamine Salbutamol may decrease the antihypertensive activities of Vincamine.
Linsidomine Salbutamol may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Salbutamol may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Salbutamol may decrease the antihypertensive activities of Tolonidine.
Endralazine Salbutamol may decrease the antihypertensive activities of Endralazine.
Cadralazine Salbutamol may decrease the antihypertensive activities of Cadralazine.
Bietaserpine Salbutamol may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Salbutamol may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Salbutamol may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Salbutamol may decrease the antihypertensive activities of Guanoclor.
Candesartan Salbutamol may decrease the antihypertensive activities of Candesartan.
Tocopherylquinone Salbutamol may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Salbutamol may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Salbutamol may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Salbutamol may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Salbutamol may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Salbutamol may decrease the antihypertensive activities of Quinaprilat.
Enalapril Salbutamol may decrease the antihypertensive activities of Enalapril.
Lercanidipine Salbutamol may decrease the antihypertensive activities of Lercanidipine.
Bosentan Salbutamol may decrease the antihypertensive activities of Bosentan.
Clonidine Salbutamol may decrease the antihypertensive activities of Clonidine.
Ambrisentan Salbutamol may decrease the antihypertensive activities of Ambrisentan.
Pinacidil Salbutamol may decrease the antihypertensive activities of Pinacidil.
Riociguat Salbutamol may decrease the antihypertensive activities of Riociguat.
Aliskiren Salbutamol may decrease the antihypertensive activities of Aliskiren.
Manidipine Salbutamol may decrease the antihypertensive activities of Manidipine.
Selexipag Salbutamol may decrease the antihypertensive activities of Selexipag.
Naftopidil Salbutamol may decrease the antihypertensive activities of Naftopidil.
Dexniguldipine Salbutamol may decrease the antihypertensive activities of Dexniguldipine.
Amlodipine Salbutamol may decrease the antihypertensive activities of Amlodipine.
Levamlodipine Salbutamol may decrease the antihypertensive activities of Levamlodipine.
Azilsartan medoxomil Salbutamol may decrease the antihypertensive activities of Azilsartan medoxomil.
Diazoxide Salbutamol may decrease the antihypertensive activities of Diazoxide.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Salbutamol.
Bethanidine Salbutamol may decrease the antihypertensive activities of Bethanidine.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salbutamol.
Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Salbutamol.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Salbutamol.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Salbutamol.
Guanabenz Salbutamol may decrease the antihypertensive activities of Guanabenz.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Salbutamol.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Salbutamol.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salbutamol.
Omapatrilat Salbutamol may decrease the antihypertensive activities of Omapatrilat.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Salbutamol.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salbutamol.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Salbutamol.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Salbutamol.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Salbutamol.
Rescinnamine Salbutamol may decrease the antihypertensive activities of Rescinnamine.
Lisdexamfetamine The risk or severity of hypertension can be increased when Salbutamol is combined with Lisdexamfetamine.
Ephedrine The risk or severity of hypertension can be increased when Salbutamol is combined with Ephedrine.
Mephentermine The risk or severity of hypertension can be increased when Salbutamol is combined with Mephentermine.
MMDA The risk or severity of hypertension can be increased when Salbutamol is combined with MMDA.
Midomafetamine The risk or severity of hypertension can be increased when Salbutamol is combined with Midomafetamine.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when Salbutamol is combined with 4-Methoxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when Salbutamol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
Tenamfetamine The risk or severity of hypertension can be increased when Salbutamol is combined with Tenamfetamine.
Chlorphentermine The risk or severity of hypertension can be increased when Salbutamol is combined with Chlorphentermine.
Dextroamphetamine The risk or severity of hypertension can be increased when Salbutamol is combined with Dextroamphetamine.
Phendimetrazine The risk or severity of hypertension can be increased when Salbutamol is combined with Phendimetrazine.
Epicaptopril The risk or severity of hypertension can be increased when Salbutamol is combined with Epicaptopril.

Target Protein

Beta-2 adrenergic receptor ADRB2
Beta-1 adrenergic receptor ADRB1
Beta-3 adrenergic receptor ADRB3

Referensi & Sumber

Synthesis reference: Toshikuni Kawazi, Masahiro Ono, Nobuko Inoue, "Salbutamol-containing plaster and method of producing same." U.S. Patent US5068103, issued February, 1984.
Artikel (PubMed)
  • PMID: 3790406
    Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP: Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol. 1986 Nov;22(5):587-93.
  • PMID: 28061018
    Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, Haydn Walters E: Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. Br J Clin Pharmacol. 2017 Jul;83(7):1436-1445. doi: 10.1111/bcp.13228. Epub 2017 Feb 8.

Contoh Produk & Brand

Produk: 438 • International brands: 12
Produk
  • AccuNeb
    Solution • 0.63 mg/3mL • Respiratory (inhalation) • US • Approved
  • AccuNeb
    Solution • 1.25 mg/3mL • Respiratory (inhalation) • US • Approved
  • Airomir
    Aerosol, metered • 100 mcg / act • Respiratory (inhalation) • Canada • Approved
  • Airsupra
    Aerosol, metered • - • Respiratory (inhalation) • US • Approved
  • Albuterol
    Aerosol, spray • 90 ug/1 • Oral • US • Approved
  • Albuterol
    Aerosol, metered • 90 ug/1 • Oral • US • Approved
  • Albuterol
    Aerosol, metered • 90 ug/1 • Oral • US • Generic • Approved
  • Albuterol
    Aerosol, metered • 90 ug/1 • Intrabronchial • US • Generic • Approved
Menampilkan 8 dari 438 produk.
International Brands
  • Aerolin
  • Asmol
  • Asthalin
  • Asthavent
  • ProAir — Teva
  • PROAIRHFA
  • Salamol
  • Ventilan — GlaxoSmithKline
  • Ventoline — GlaxoSmithKline
  • VENTOLINHFA

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul